ArriVent BioPharma/$AVBP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Ticker
$AVBP
Sector
Primary listing
Employees
-
Headquarters
Website
AVBP Metrics
BasicAdvanced
$809M
-
-$4.02
-
-
Price and volume
Market cap
$809M
52-week high
$34.51
52-week low
$15.47
Average daily volume
326K
Financial strength
Current ratio
12.739
Quick ratio
12.029
Total debt to equity
0.039
Profitability
Management effectiveness
Return on assets (TTM)
-23.41%
Return on equity (TTM)
-50.06%
Valuation
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-5.366
Free cash flow yield (TTM)
-18.64%
Free cash flow per share (TTM)
-3.718
Growth
Earnings per share change (TTM)
-14.41%
What the Analysts think about AVBP
Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.
Bulls say / Bears say
ArriVent has completed enrollment for its pivotal Phase 3 FURVENT trial for furmonertinib in first-line EGFR exon 20 insertion NSCLC, with 398 patients globally, and expects to report topline data in early 2026. This represents a significant de-risking milestone, with Wall Street analysts maintaining a strong buy consensus (Investing.com).
Interim Phase 1b PACC data have confirmed furmonertinib’s activity in EGFR PACC mutant NSCLC, and ArriVent expects to enroll the first patient in the pivotal Phase 3 ALPACCA study in the second half of 2025, highlighting strategic diversification beyond exon 20 insertions (ArriVent Q2 2025 Results).
As of June 30, 2025, ArriVent had $254.5 million in cash and investments, and raised an additional $81.1 million in July 2025, providing funding through mid-2027, which reduces near-term dilution risk for its ongoing development programs (ArriVent Q2 2025 Results).
The competitive landscape has intensified following the FDA's accelerated approval of sunvozertinib (Zegfrovy) on July 2, 2025, which achieved a 46% overall response rate and an 11.1-month median duration of response in platinum-pretreated EGFR exon 20 insertion NSCLC, posing a threat to ArriVent’s potential market share for furmonertinib (FDA).
ArriVent faces over a year of binary trial risk, as topline results from the pivotal FURVENT Phase 3 study of furmonertinib in first-line EGFR exon 20 insertion NSCLC are not expected until early 2026 (Investing.com).
Despite ending Q2 2025 with $254.5 million in cash and investments and an $81.1 million offering in July, the expenditures for two global Phase 3 studies and multiple ADC trials will increase cash burn, likely requiring further external funding before commercialization (ArriVent Q2 2025 Results).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
AVBP Financial Performance
Revenues and expenses
AVBP Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ArriVent BioPharma stock?
ArriVent BioPharma (AVBP) has a market cap of $809M as of October 07, 2025.
What is the P/E ratio for ArriVent BioPharma stock?
The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of October 07, 2025.
Does ArriVent BioPharma stock pay dividends?
No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next ArriVent BioPharma dividend payment date?
ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.
What is the beta indicator for ArriVent BioPharma?
ArriVent BioPharma (AVBP) does not currently have a Beta indicator.